Adverse Long-Term Outcomes and an Immune Suppressed Endotype in Sepsis Patients with Reduced Interferon-γ ELISpot: A Multicenter, Prospective Observational Study

4

Evan A. Barrios¹, Monty B. Mazer⁵, Patrick McGonagill⁶ Christian B. Bergmann^{3,*}, Michael D. 5 Goodman³, Robert W. Gould¹¹, Mahil Rao¹⁰, Valerie Polcz¹, Ruth Davis¹, Drew Del Toro⁴, 6 Marvin Dirain¹, Alexandra Dram⁴, Lucas Hale¹¹, Mohammad Heidarian¹², Tamara A. Kucaba¹², 7 Jennifer P. Lanz¹, Ashley McCray¹, Sandra Meszaros⁴, Sydney Miles⁴, Candace Nelson¹¹, 8 Ivanna Rocha¹, Elvia E Silva⁷, Ricardo Ungaro¹, Andrew Walton⁴, Julie Xu¹², Leilani Zeumer-9 Spataro¹, Anne M. Drewry⁴ Muxuan Liang², Letitia E. Bible¹, Tyler Loftus¹, Isaiah Turnbull⁴, 10 Philip A. Efron¹, Kenneth E. Remy⁵, Scott Brakenridge¹⁵, Vladimir P. Badovinac^{7,8,9}, Thomas S. Griffith^{12,13,14}, Lyle L. Moldawer^{1,16}, Richard S. Hotchkiss⁴, Charles C. Caldwell³ 11 12 13

- ¹Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida
 College of Medicine, Gainesville, Florida 32610 USA
- ²Department of Biostatistics, University of Florida College of Medicine, Gainesville, Florida
 32610 USA
- ³Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267,
 USA.
- ⁴Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri
 63110 USA
- ²⁵
 ⁵Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland,
 Ohio 44106USA
- 28

- ²⁰⁶Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242 30 USA.
- 31
- ⁷Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa
 52242 USA.
- 34
- ⁸Interdisciplinary Program in Immunology, University of Iowa Carver College of Medicine, Iowa
 City, Iowa 52242 USA.
- ⁹Experimental Pathology Ph.D. Program, University of Iowa Carver College of Medicine, Iowa
 City, Iowa 52242 USA.
- 40
- ¹⁰Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa
 52242 USA.
- 43
- ⁴⁴ ¹¹Department of Anesthesiology, University of Minnesota Medical School, Minneapolis,
- 45 Minnesota 55455 USA.

2

- ⁴⁶
 ⁴⁷ ¹²Department of Urology, University of Minnesota Medical School, Minneapolis, Minnesota
 ⁴⁸ 55455, USA.
- ⁴⁹
 ⁵⁰ ¹³Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota
 55455 USA.
- ¹⁴Minneapolis VA Healthcare System, Minneapolis, Minnesota 55417, USA
- ¹⁵Department of Surgery, Harborview Medical Center, University of Washington School of
 Medicine, Seattle, Washington 98133 USA
- * current address: Department of Anesthesiology and Critical Care Medicine, University of Ulm,
 Ulm Germany.
- 61 Running head: ELISpot Use in Critical Illness
- 63 Key words: critical illness, late mortality, procalcitonin, IL-6, prediction modeling.
- 65 Correspondence should be directed to:
- ¹⁶Corresponding Author Responsible for Content:
- 68

52

54

57

60

62

64

66

- 69 Lyle L. Moldawer, Ph.D.
- 70 Sepsis and Critical Illness Research Center
- 71 Department of Surgery
- room 6116, Shands Hospital
- 73 University of Florida College of Medicine
- 74 Gainesville, Florida 32610-0019
- 75 moldawer@surgery.ufl.edu
- 76 **35**2*,* **265-0494**
- 77
- 78

79 **Conflict of Interest Statements:**

- 80 Evan A, Barrios, M.D. reports institutional support for salary from a National Institute of
- General Medical Sciences training grant in burns, trauma and sepsis (T32 GM-008721) (PAE).
- 82 Monty B. Mazer, M.D. is a member of Immune Functional Diagnostics, LLC and receives no
- direct financial compensation. Immune Functional Diagnostics, LLC is developing predictive metrics in critical illness and this technology is evaluated in this research.
- 85 Patrick McGonagill M.D. reports no conflicts of interest.
- ⁸⁶ Christian B. Bergmann, M.D. is supported by grants from the Deutsche
- 87 Forschungsgemeinschaft (German Research Foundation) (BE 7016/1-1).
- 88 Michael D. Goodman, M.D. reports institutional support for salary from the National Institute of

- 3
- 89 General Medical Sciences (R01 GM-124156) and the Department of Defense (G102983-
- 90 6263608307-1).
- 91 Robert W. Gould, M.D. reports no conflicts of interest.
- 92 Mahil Rao M.D., Ph.D. reports no conflicts of interest.
- ⁹³ Valerie Polcz, M.D. reports institutional support for salary from a National Institute of General
- 94 Medical Sciences training grant in burns, trauma and sepsis (T32 GM-008721) (PAE).
- 95 Ruth Davis, B.S.N, R.N. reports no conflicts of interest.
- 96 Drew Del Toro, M.D. reports no conflicts of interest.
- 97 Marvin Dirain, M.S. reports no conflicts of interest.
- 98 Alexandra Dram reports no conflicts of interest.
- 99 Lucas Hale, B.A. reports no conflicts of interest.
- 100 Mohammad Heidarian, M.S. reports no conflicts of interest.
- 101 Tamara A. Kucaba, B.S. reports no conflicts of interest.
- 102 Jennifer P. Lanz, M.S.N., R.N. reports no conflicts of interest.
- 103 Ashley McCray, R.N. reports no conflicts of interest.
- 104 Sandra Meszaros reports no conflicts of interest.
- 105 Sydney Miles, B.S. reports no conflicts of interest.
- 106 Candace Nelson, B.A. reports no conflicts of interest.
- 107 Ivanna Rocha, M.P.H. reports no conflicts of interest.
- 108 Elvia E Silva, M.S. reports no conflicts of interest.
- 109 Ricardo Ungaro, B.S. reports no conflicts of interest.
- 110 Andrew Walton, M.S. reports no conflicts of interest.
- 111 Julie Xu, B.S. reports no conflicts of interest.
- 112 Leilani Zeumer-Spataro, B.S. reports no conflicts of interest.
- 113 Muxuan Liang, Ph.D. reports no conflicts of interest.
- 114 Isaiah Turnbull, M.D is a member of Immune Functional Diagnostics, LLC and receives no
- direct financial compensation. Immune Functional Diagnostics, LLC is developing predictive
- 116 metrics in critical illness and this technology is evaluated in this research. He is also supported
- by R35 GM-133756 from the National Institute of General Medical Sciences.
- 118 Letitia E. Bible, M.D. reports no conflict of interest.
- Tyler Loftus, M.D. is supported by R01 GM-149657 from the National Institute of GeneralMedical Sciences.
- 121 Philip A. Efron, M.D. is supported by grants R35 GM-140806, T32 GM-008721 and RM GM-
- 122 139690 awarded by the National Institute of General Medical Sciences.

- 123 Kenneth E. Remy, M.D., M.S. is a member of Immune Functional Diagnostics, LLC and
- receives no direct financial compensation. Immune Functional Diagnostics, LLC is developing
- predictive metrics in critical illness and this technology is evaluated in this research.
- 126 Scott Brakenridge, M.D., M.S.C.S. is funded by R35 GM-134880 from the National Institute of
- 127 General Medical Sciences. Dr. Brakenridge and the University of Florida may receive royalty
- income based on a technology developed by Dr. Brakenridge and others and licensed by
- 129 Washington University in St. Louis to IFDx LLC. That technology is evaluated in this research.
- 130 Vladimir P. Badovinac Ph.D.is funded by R35 GM-134880 from the National Institute of
- 131 General Medical Sciences.
- 132 Thomas S. Griffith, Ph.D. is funded by R35 GM-140881 from the National Institute of General
- Medical Sciences and the recipient of a Research Career Scientist award (IK6BX006192) from the Department of Veteran Affairs.
- Lyle L. Moldawer, Ph.D. is supported by NIH grants RM1 GM-139690, R01GM-132364 and
- RF1 NS128626. Dr. Moldawer and the University of Florida may receive royalty income based
- on a technology developed by Dr. Moldawer and others and licensed by Washington University
 in St. Louis to IFDx LLC. That technology is evaluated in this research.
- 139 Richard S. Hotchkiss, M.D. Dr. Hotchkiss and Washington University in St. Louis may receive
- royalty income based on a technology developed by Dr. Hotchkiss and others and licensed by
- 141 Washington University in St. Louis to IFDx LLC. That technology is evaluated in this research.
- He is also supported by R35 GM-126928, awarded by the National Institute of General Medical
 Sciences.
- 144 Charles C. Caldwell, Ph.D. Dr. Caldwell and the University of Cincinnati may receive royalty
- income based on a technology developed by Dr. Caldwell and others and licensed by
- 146 Washington University in St. Louis to IFDx LLC. That technology is evaluated in this research.
- 147

148 Abbreviations

- 149 ALC, absolute lymphocyte count
- 150 AMA, discharged against medical advice
- 151 AUROC, area under the receiver-operator curve
- 152 CINS, critically ill, nonseptic cohort of patients
- 153 CTSI, UF Clinical and Translational Science Institute
- 154 ELISpot, enzyme-linked immunospot assay
- 155 HLA-DR, human leukocyte antigen DR isotype
- 156 IFN γ , interferon- γ
- 157 IL-6, interleukin 6
- 158 IL-10, interleukin 10
- 159 IPR, in-patient rehabilitation
- 160 LTAC, long-term acute care facility
- 161 mAb, monoclonal antibody
- 162 PBMC, peripheral blood mononuclear cell
- 163 SEPSIS, critically ill, sepsis cohort of patients
- 164 SFU, ELISpot spot forming units
- 165 SNF, specialized nursing facility
- 166 SOFA, sequential organ failure assessment score
- 167 sPD-L1, soluble programmed death ligand-1
- 168 SS, ELISpot spot size
- 169 TE, ELISpot total expression
- 170

6

171 Abstract

Background: Sepsis remains a major clinical challenge for which successful treatment
requires greater precision in identifying patients at increased risk of adverse outcomes
requiring different therapeutic approaches. Predicting clinical outcomes and immunological
endotyping of septic patients has generally relied on using blood protein or mRNA biomarkers,
or static cell phenotyping. Here, we sought to determine whether functional immune
responsiveness would yield improved precision.

178 **Methods:** An *ex vivo* whole blood enzyme-linked immunosorbent (ELISpot) assay for cellular 179 production of interferon- γ (IFN- γ) was evaluated in 107 septic and 68 non-septic patients from 180 five academic health centers using blood samples collected on days 1, 4 and 7 following ICU 181 admission.

182 **Results:** Compared with 46 healthy subjects, unstimulated and stimulated whole blood IFNy expression were either increased or unchanged, respectively, in septic and nonseptic ICU 183 184 patients. However, in septic patients who did not survive 180 days, stimulated whole blood IFNγ expression was significantly reduced on ICU days 1, 4 and 7 (all p<0.05), due to both 185 significant reductions in total number of IFN γ -producing cells and amount of IFN γ produced 186 187 per cell (all p<0.05). Importantly, IFNy total expression on day 1 and 4 after admission could discriminate 180-day mortality better than absolute lymphocyte count (ALC), IL-6 and 188 procalcitonin. Septic patients with low IFN₂ expression were older and had lower ALC and 189 190 higher sPD-L1 and IL-10 concentrations, consistent with an immune suppressed endotype. 191 **Conclusions:** A whole blood IFN_Y ELISpot assay can both identify septic patients at increased

risk of late mortality, and identify immune-suppressed, sepsis patients.

193 (word count: 249)

- **Trial Registry:** Because the study is a prospective observational study, and not a clinical trial,
- registration with *clinical trials.gov* is not required.

8

199 Introduction

200 Sepsis remains one of the most common causes of critical illness and too often leads to death and morbidity (1-3). Importantly, sepsis is a pathophysiologic host response to microbial 201 infection associated with organ injury and dysfunction (4). However, the nature and magnitude 202 of the host response to sepsis is highly variable depending upon the subject's age. 203 comorbidities and source and severity of microbial infection. Although sepsis is frequently 204 205 associated with an early exaggerated inflammatory response (5), persistent inflammation (6,7), 206 coagulopathy (8), prolonged immune suppression (3,6,9-12), and lean tissue wasting (13,14), the contribution of these individual responses to the overall outcome of the patient is still 207 208 unresolved (15.16). Precision medicine has been proposed as a tool to identify which 209 immunologic endotype drives organ injury and is an appropriate target for therapeutic intervention (17). Biomarkers, based on static blood cell phenotypes, protein and 210 211 transcriptomic metrics have been commonly used to endotype critically ill patients with and without sepsis (15,17-20). 212

Enzyme-Linked ImmunoSpot assay (ELISpot) is a widely used immunological technique that 213 enables the detection and quantification of individual cells responding to external receptor-214 specific and nonspecific stimulants and secreting specific proteins, particularly cytokines (21). 215 This method is important for studying the immune response at the single-cell level, offering 216 217 valuable insights into immune cell function, and immune-related diseases. Its ability to analyze immune responses at the cellular level makes it particularly suitable for monitoring immune 218 219 system functionality in sepsis. In the current report, we examined the extent to which whole 220 blood ELISpot production of interferon γ (IFN γ) can identify immune suppressed, critically ill patients at increased risk of death. 221

222 Materials and Methods

This multi-center, prospective diagnostic and prognostic study conducted between February 223 224 23, 2021, and July 22, 2022, enrolled two cohorts of critically ill patients at the time of ICU admission. The first cohort included patients with a suspected diagnosis of sepsis admitted to 225 the ICU (SEPSIS). The second cohort included critically ill patients admitted to the ICU without 226 currently suspected sepsis (Critically III, Non-Septic; CINS), but considered at high risk for 227 subsequent infection (e.g., postoperative, severe trauma). Patient enrollment is shown in 228 229 Figure 1, consistent with Enhancing the Quality and Transparency of Health Research Standards for Reporting of Diagnostic Accuracy (STARD) reporting guidelines (22). All patients 230 231 were managed under institutional clinical management protocols. Centralized ethics approval 232 was obtained from the University of Florida Institutional Review Board (#IRB 202000924) which served as the sponsoring institution. Written informed consent was obtained from each 233 234 patient or their proxy decision-maker at individual clinical sites.

A heparinized blood collection tube (Becton Dickinson) was obtained within the first three days of ICU admission (labeled as day 1), and on subsequent days 3 through 5 (labeled as day 4), and weekly thereafter (± 2 days). Self- or proxy-reported race and ethnicity category data were collected as per National Institutes of Health reporting guidelines and requirements.

Inclusion criteria consisted of ICU admission from the emergency department for communityacquired sepsis or severe trauma (patients with Injury Severity Scores >15, hemorrhagic
shock, and/or severe chest trauma), as well as non-trauma, postoperative ICU admission, ICU
transfer from the emergency department and inpatient transfer from ward to ICU.

243 Sepsis was defined according to Sepsis-3 criteria (4), and all subjects were clinically

adjudicated at the individual participating sites. Patients admitted to the ICU for critical illness,
non-sepsis (CINS) were also adjudicated to rule out sepsis. A detailed summary of inclusion
and exclusion criteria is provided in the Supplemental Materials and Methods.

Healthy control subjects were recruited at each of the clinical sites. Efforts were made to age, sex and race-ethnicity match the healthy control subjects to the SEPSIS cohort. Individuals with autoimmune diseases being treated with biologic immune modulators were excluded, as were individuals who had received anti-neoplastic therapies or diagnosed with cancer within

the past six months. Vulnerable populations were also excluded.

252 Primary Outcomes and Clinical Adjudication

The primary clinical outcome for ELISpot was 180-day mortality, determined via clinical records and telephone follow-up with the patient, their proxy, or their designated contact, and cross-checked through the US Social Security Death Index. We analyzed temporal trends of ELISpot in both SEPSIS and CINS patients but compared estimated performance of predictive models primarily in the SEPSIS patients, as 180-day mortality in the CINS cohort was <4%. Final sepsis or CINS adjudication was performed by physician-investigator determination at each clinical site at completion of each patient's hospital course.

260 Secondary clinical outcome variables included all-cause (in hospital, 30-day) mortality,

development of chronic critical illness (CCI), secondary infections, and poor discharge

disposition. Inpatient clinical trajectory was defined as "early death", "rapid recovery", or "CCI".

263 CCI was defined as an ICU length of stay \geq 14 days with evidence of persistent organ

dysfunction (SOFA score \geq 2) (23). Hospitalized patients who died after an ICU length of stay

265 >14 days from the index hospitalization were also classified as CCI. Poor disposition was

defined as discharge to a skilled nursing facility (SNF), long-term acute care facility (LTAC), or
 hospice. Secondary infections were defined as per the US Centers for Disease Control and
 Prevention criteria.

269 ELISpot

ELISpot assays were conducted using the human IFNγ Immunospot[®] kit (CTL Inc., Cleveland, OH) with several important modifications including the use of diluted whole blood as previously described (21). Specifically, 100 µl of heparinized whole blood was diluted 1:10 with kit buffer and 50 µl of the diluted sample was added to each well. Samples were incubated in wells containing either buffer alone or a soluble anti-CD3/anti-CD28 (125 ng/ml/1.25 µg/ml) mAb agonist (BioLegend, San Diego, CA). Samples were assayed in duplicate. Optimal concentrations of agonist were determined in preliminary studies (see **Supplemental**

277 Materials and Methods).

Samples were quantitated using a CTL S6 Entry or S6 FluoroCore[™] ELISpot reader at each 278 clinical site. To assure comparable results, the instruments were harmonized by CTL Inc. prior 279 to study using an external standard across all five clinical sites. Results are presented as the 280 number of spot-forming units (SFU), spot size (μm^2 ; SS) and total expression (μm^2 ; TE) a 281 product of the number of spots and mean spot size using the Immunospot[®] SC software suite 282 (version 7.0.30.4). Spot forming units represent individual blood cells expressing IFN γ and spot 283 size is an indication of the amount of IFNy produced per cell. In subsequent analyses, the 284 number of IFNy-producing cells was adjusted for each individual patient's absolute lymphocyte 285 286 count to yield the percentage of total lymphocytes expressing IFNy.

287 Additional Laboratory Analyses

- 288 Whole blood total leukocyte and absolute lymphocyte counts were determined on EDTA-
- anticoagulated whole blood at the individual clinical sites either using their hospital's Clinical
- and Diagnostics Laboratory or a research Beckman-Coulter Dx500 or Dx900 hemocytometer
- 291 (Brea, CA). Cytokine and additional plasma protein analyses were conducted at the University
- of Florida Sepsis and Critical Illness Research Center (SCIRC) where they were determined in
- ²⁹³ batch using the Luminex MagPix[®] (Austin, TX) platform using commercial reagents.
- 294 Excess sample was stored at the Biorepository of the Clinical and Translational Science

Institute (<u>https://www.ctsi.ufl.edu/research/laboratory-services/ctsi-biorepository-2/</u>) where it is
 available to the scientific community under guidelines promulgated by the National Institute of
 General Medical Sciences.

298 Data Collection and Analysis

Clinical data collection was conducted at each site and entered into a web-based electronic 299 case report form created on the REDCap[™] platform managed by the University of Florida 300 301 Clinical and Translational Science Institute (CTSI). Access to the case report form was 302 password protected and limited to only approved research staff, and all interactions with the database were recorded. Peer-to-peer communication allowed approved individuals at all five 303 304 sites access to their own data and de-identified data from the other four clinical sites. Research data, including ELISpot, total leukocyte and absolute lymphocyte counts, and plasma protein 305 and cytokine data were uploaded into the case report forms from the University of Florida 306 SCIRC. Data managers at the SCIRC were responsible for creating final locked datasets for 307 308 subsequent analysis.

309 Statistical Analysis

310	Descriptive data are presented as frequencies and percentages or medians and IQRs. The
311	Fisher exact test and Mann-Whitney or Kruskal-Wallis ANOVA tests were used for categorical
312	and continuous variables, respectively. Area under the receiver operating characteristics curve
313	(AUROC) values with 95% confidence intervals (computed with 2000 stratified bootstrap
314	replicates) were used to assess discrimination. Univariable and multivariable logistic
315	regression were performed to assess whether the combination of metrics improved overall
316	performance. Post hoc tests were performed for continuous outcomes using the Dunn test. For
317	post hoc analyses of categorical outcomes, separate 2×2 Fisher exact tests were performed.
318	All significance tests were 2-sided, with a raw $p \le 0.05$ considered statistically significant.
319	Analyses were performed using the R Project statistical package, version 4.1.0 (R Project for
320	Statistical Computing).

321 Results

322 Patient Characteristics

Demographic characteristics of the 175 enrolled patients (99 men [57%] and 76 women [43%]) and 46 healthy control subjects (16 men [36%], 30 women [64%]) are summarized in **Table 1**. The overall cohort included 107 and 68 patients in the SEPSIS and CINS cohorts, respectively. Patient characteristics were similar across all three cohorts with the exception that the healthy control subjects were more predominantly female and younger, and SEPSIS patients had a higher Charlson comorbidity index than CINS subjects (**Table 1**). Within the CINS cohort ([n]=[68]), reason for ICU admission was identified in **Supplemental Table 1**.

Table 2 shows clinical outcomes for the SEPSIS and CINS patients. Hospital length of stay
(p<0.02), incidence of secondary infections (p<0.001), development of CCI (p<0.001), and in-
hospital mortality (p<0.01) were all significantly higher in SEPSIS than in CINS patients.
Disposition at discharge also significantly differed between SEPSIS and CINS patients, as did

334 **30-** and 180-day mortality (both p<0.01).

335 IFNγ Production by Unstimulated and anti-CD3/CD28 mAb-Stimulated Whole Blood

336 Comparison of the first sample collected (days 1-3 post ICU admission) among the three 337 cohorts revealed considerable heterogeneity in the individual subject response, irrespective of 338 the cohort. Surprisingly, as a group, spontaneous IFNy production in *unstimulated* whole blood was significantly increased from SEPSIS and CINS patients than from healthy subjects at all 339 340 sampling intervals (days 1, 4 and 7), despite a significant reduction in lymphocyte numbers (Figure 2, Supplemental Figure 1). This was reflected generally by an increased number of 341 IFN₂-producing cells (SFU) (all p<0.05;), although the amount of IFN₂ produced by each cell 342 343 (SS) was increased on day 4 (**Figure 3**). When the total number of IFN γ producing cells was adjusted for the absolute lymphocyte count, the percentage of lymphocytes expressing IFNy 344 was further increased significantly in both SEPSIS and CINS (p<0.001; supplemental Figure 345 **2**). There was no difference between unstimulated IFN γ expression between the SEPSIS and 346 CINS cohorts. 347

Ex vivo stimulation of the whole blood from the three cohorts with agonist anti-CD3/CD28 mAb
 resulted in expected increases in the total expression of IFNγ produced when compared with
 unstimulated samples. There were also increase in the total amount of IFNγ produced per unit

volume of blood on days 4 and 7 when comparing CINS to healthy subjects (Figure 2). This
 increased IFNγ expression was only seen on day 4 in SEPSIS patients.

353 Influence of Outcome on ELISpot Responses

SEPSIS subjects had a greater in-hospital, 30- and 180-day mortality when compared to CINS
 patients (**Table 2**). In addition, the incidence of secondary infections, development of CCI and
 an adverse discharge disposition were all significantly greater in SEPSIS than CINS patients
 (all p<0.05).

SEPSIS subjects who died within 180 days of ICU admission did not differ from surviving 358 359 patients based on their admission or day 1 SOFA scores or total leukocyte numbers, even though non-surviving SEPSIS patients were significantly older and had higher Charlson 360 comorbiditive scores (both p<0.05; **Supplemental Table 1**). Interestingly, there were marked 361 differences in the IFN_y production from stimulated whole blood between sepsis subjects who 362 survived or did not survive 180 days. Both the absolute number (SFU) and percentage of IFNy 363 364 producing cells, and the spot size (SS) were significantly lower, and therefore, total expression (TE) was reduced in non-surviving versus surviving SEPSIS patients (all p<0.05; Figure 4). 365 This reduction in expression was, in general, sustained through day 4 in non-survivors (Figure 366 367 4). After 7 days, there were too few ICU-remaining patients to continue the comparison (data not shown). Surprisingly, IFNy production from unstimulated whole blood did not differ between 368 surviving and non-surviving patients at any time point (*data not shown*). There also did not 369 appear to be any significant changes in ELISpot responses (both stimulated and unstimulated) 370 371 over time in either surviving or non-surviving individual SEPSIS patients (data not shown).

16

Univariate and Multivariate Prediction Models for Long-term Survival and Secondary Outcomes.

Because of the differences in IFNy expression between surviving and non-surviving SEPSIS 374 375 patients, ELISpot AUROCS were evaluated for their discriminatory prediction of long-term survival (180 day), as well as secondary outcomes, and compared to clinical indices (SOFA, 376 Charlson comorbidity scores), total white blood cell and absolute lymphocyte counts, and 377 378 plasma protein markers (selected cytokines, procalcitonin, and sPD-L1) in the SEPSIS 379 patients. Similar combined SEPSIS and CINS analyses could not be performed due to the low 380 mortality in CINS patients. Results are presented in **Table 3** and **Figure 5**. Similar to data reported by ourselves and others (24-26), the most consistent discriminator of 381 180-day mortality was the Charlson comorbidity score (AUROC; 0.824 [CI 0.700-0.948], which 382 383 also discriminated in-hospital mortality (0.762 [0.611-0.912]) and development of CCI (0.713 [0.594-0.832]), but not the incidence of secondary infection (0.549 [0.426-0.673]. Importantly, 384 stimulated total IFN_y expression at day 1 and day 4 did not significantly differ from the 385 Charlson comorbidity score with AUROCs of 0.730 (0.601-0.859) and 0.794 (0.691-0.897), 386 respectively. Total IFNy expression on day 4 also discriminated in-hospital mortality with an 387 AUROC of 0.743 (0.615-0.830), but it was not a strong discriminator of either development of 388 CCI or incidence of secondary infections. 389

For total stimulated IFNγ expression, the components contributing to its discriminative power
for 180-day mortality were both the number of IFNγ producing cells (SFU; Day 1, 0.707 [0.5680.846] and the amount of IFNγ produced by individual cells (SS; Day 1, 0.707 [0.568-0.846]).

393 The discriminatory power of the ELISpot total expression (TE) for predicting both in-hospital 394 and 180-day mortality was much greater than seen for either absolute lymphocyte count (ALC), IL-6, or procalcitonin at either day 1 or day 4, or for changes in these parameters 395 between days 1 and 7 (Table 3). In addition, the last ELISpot measurement obtained from the 396 patient prior to discharge or death (usually day 7 or later) was also found to be not as 397 398 discriminatory as the earlier day 1 and 4 measurements (*data not shown*). Setting the threshold for day 1 and day 4 stimulated total IFN_y expression at approximately 399 80% sensitivity to discriminate 180-day survival, it was possible to assess the 400 immunosuppressive endotype of those SEPSIS patients with reduced ELISpot total expression 401 402 (**Table 4**). These individuals were older and had absolute lymphocyte counts significantly lower 403 at both days 1 and 4 than SEPSIS patients above the ELISpot threshold. In addition, plasma sPD-L1 concentrations were significantly higher on day 4. Patients below the ELISpot 404 405 threshold also had in-hospital and 180-day mortality, and development of CCI at a markedly 406 higher frequency than those individuals above the threshold (all p<0.05). 407 Finally, to examine whether ELISpot could improve the discriminatory power of standard clinical indices (SOFA and Charlson comorbidity scores), single and multivariate logistic 408 409 regression analyses were performed and the AUROCs of the models were calculated by a 410 four-fold cross-validation procedure (**Table 5**). Model I was built on baseline Charlson comorbidity data and day 1 SOFA scores yielding AUROCs for 180-day mortality (0.911 411 412 [0.858-0.965]); the odds ratios show baseline Charlson comorbidity data and day 1 SOFA

scores are significant predictors for 180-day mortality (**Table 5**). Model II was built on

stimulated total IFNγ expression from Day 4 yielding AUROCs for 180-day mortality (0.794

18

[0.732-0.855]); the odds ratios show stimulated total IFNγ expression is a significant predictor
for 180-day mortality (Table 5). Although ELISpot data show significant odds ratios in Model II,
the addition of stimulated total IFNγ expression to the model built on standard score indices
(Model III) did not significantly increase either the AUROC or the odds ratio for 180-day (0.915
[0.851-0.979] or in-hospital mortality (0.883 [0.801-0.964]), or development of CCI (0.861
[0.830-0.892]) (Table 5).

421 Discussion

422 Key Findings

This prospective, multi-center observational study has demonstrated that the adaptive immune 423 response to critical illness, as defined by ex vivo whole blood production of IFNy in response to 424 T cell receptor stimulation, varied in response to critical illness (Figures 2, 3) and could also 425 discriminate long-term outcomes (Figure 5, Table 3). Spontaneous IFN_γ production by diluted 426 whole blood was significantly increased in critically ill patients, irrespective of whether the 427 critically ill patients were septic. In addition, when whole blood was stimulated ex vivo with a T 428 429 cell receptor agonist, IFNy production increased dramatically in both healthy and critically ill cohorts (both SEPSIS and CINS). However, stimulated ELISpot IFNy total expression early in 430 431 the admission to the ICU significantly differed between septic patients who survived 180 days and those who died, and this reduction in total expression in non-surviving septic patients was 432 due to both reductions in the total number of IFNy producing blood cells and the amount of 433 IFNy produced by individual cells (Figure 4). Importantly, day 1 and day 4 measurements were 434 more discriminatory than later measurements. Using univariate modeling, stimulated ELISpot 435

436	total expression measured in the first week of admission (sampling days 1 and 4) could
437	differentiate 180-day mortality as well as SOFA and Charlson comorbidity scores, and
438	markedly better than blood ALC, procalcitonin, IL-6 and sPD-L1 concentrations (Table 3).
439	Septic patients who had low stimulated ELISpot total IFN γ expression at days 1 and 4 had an
440	immunosuppressed endotype, as reflected in being older, and having lower ALC counts,
441	higher plasma sPD-L1, and increased incidence of chronic critical illness, in-hospital and late
442	mortality (Table 4). However, in multivariate models, stimulated ELISpot total IFNγ expression
443	did not significantly improve the discrimination between 180-day survival in models built with
444	SOFA and Charlson comorbidity scores (Table 5).

445 **Context**

446 ELISpot has emerged as a powerful method to assess immunological status in a variety of clinical disorders (27-30), including sepsis and critically ill patients (20,21,31,32). It offers 447 several theoretical advantages over other current metrics – for example, cell phenotypes (such 448 as ALC (33-36) and HLA-DR expression on CD14⁺ blood cells (37,38)), plasma protein 449 concentrations (such as procalcitonin (39-42), IL-6 (43-45) and sPD-L1 (46,47)) or blood 450 451 transcriptomics (26,48,49) – used to predict both the severity of the host response and the 452 immunosuppressed endotype. ELISpot, unlike these static measures, assesses one component of the functional status of the host protective immune response. In the present 453 study, ELISpot revealed the capacity of T cells in the blood to produce IFNy with and without 454 stimulation through the T cell receptor. 455

This study is not the first to demonstrate reduced IFNγ ELISpot expression in sepsis patients,
 especially in those with adverse clinical outcomes (20,21,50). However, in contrast to these

20

previous studies, we used diluted whole blood in our ELISpot assay instead of isolated PBMCs 458 and observed increased IFNy production in both unstimulated and stimulated whole blood from 459 critically ill patients. There are two key advantages of using diluted whole blood in the ELISpot. 460 First, the use of whole blood permits the assay to take place with the entire blood composition 461 (i.e., all leukocytes, erythrocytes, platelets, and plasma proteins and metabolites) maintained. 462 Responses to critical illness and ex vivo stimulation may be either direct or be mediated via 463 cell-cell communication and/or plasma mediators. Traditional processing of blood by density 464 gradient centrifugation separates the PBMC from the neutrophils, platelets, and plasma. 465 Second, it is a simpler and more 'rapid' assay to set up because there is no required cell 466 467 isolation step.

468 On days 1-7, both the CINS and SEPTIC patients had reduced ALC as compared to healthy controls (Supplemental Figure 1). Surprisingly, despite this lymphopenia, the number of 469 470 lymphocytes spontaneously producing IFNy was higher in both CINS and SEPSIS patients 471 versus healthy controls at all three time points (Figure 2). Day 1 stimulated IFNy SFU, spot 472 size (SS), and total expression did not differ between cohorts. However, on Day 4, both the 473 number of cells producing IFNy as well as total expression of IFNy was higher in both the CINS and SEPSIS cohorts as compared healthy subjects. On Day 7, the number of cells 474 475 producing IFNy remained higher in the CINS and SEPSIS cohorts. Of note, the amount of IFNy 476 produced on a per cell basis (reflected by spot size) was lowest in the SEPSIS cohort with total expression similar to healthy controls. 477

Given the considerable amount of data showing sepsis can evolve into an immunosuppressed
state, it was surprising to see both the spontaneous and stimulated IFNγ production increase

in septic patients (early after admission) versus healthy subjects. There are several likely
explanations for this apparent paradox. The first potential explanation relates to timing;
specifically, the data presented herein came from blood samples collected within the first 7
days after ICU admission. It is difficult to determine exactly when the sepsis-induced
hyperinflammation transitions to a state of immunoparalysis, but it is tempting to speculate that
our assessment of immune fitness was still within the window of hyperinflammation and
exacerbated immune cell activity.

A second explanation has been termed "bystander activation" (51,52). The inflammatory 487 response that develops during infection has a capacity to trigger antigen-experienced effector 488 and/or memory CD8⁺ T cells present in a T cell receptor-independent and cytokine-dependent 489 manner. A number of cytokines including IL-12, IL-15, TNF α , and IL-18 induce CD8⁺ T cell 490 activation and resultant IFNy production (53). Thus, the sepsis cytokine milieu likely primes 491 492 pre-existing, effector and memory CD8⁺ T cells to produce IFNy in a cognate antigen-493 independent fashion (Figure 2). In addition, these cytokine-primed effector/memory CD8⁺ T 494 cells will also respond with IFNy production to a myriad of cytokines produced ex vivo during 495 anti-CD3/CD28 stimulation.

A third explanation may lie in the differences in the lymphocyte subsets present in the peripheral blood of healthy subjects versus CINS and SEPSIS patients at the time of blood collection. *De novo* clonal expansion of pathogen-specific effector CD8⁺ T cells in response to sepsis-inducing pathogens and resultant inflammation leads the potential for a preponderance of active response effector cells – especially early in the septic timeline. In contrast, healthy control volunteers are more likely to have 'resting' naïve and memory T cells and a minimal (if

502	any) increase in inflammatory cytokines. Consequently, the number of T cells capable of
503	rapidly responding to polyclonal and/or bystander cytokine stimulations and produce IFN γ in

the ELISpot assay is increased in SEPSIS patients compared with healthy subjects.

505 Current Work

The current studies add to the body of information suggesting ELISpot examining whole blood
 production of IFNγ can both discriminate long-term mortality and identify those patients who
 may benefit from therapeutic interventions targeting adaptive immunity.

509 Limitations

This study has several limitations. Despite multicenter enrollment, sample sizes were still 510 relatively small for discriminative modeling. Over the past two decades, improved in-hospital 511 management has reduced the number of adverse events and in-hospital mortality to sepsis 512 513 and critical illness (25,54). Discriminatory analyses could only be conducted in the SEPSIS cohort as CINS patients had very low in-hospital (1%) and 180-day mortality (4%) (Table 2). 514 515 Second, every effort was made to match healthy control subjects to the SEPSIS and CINS 516 cohorts, but the healthy donors used in this study were, as a group, significantly younger and 517 more frequently female (**Table 1**). Median ages in the healthy control cohort were greater than 518 45 years, a break point often determined to be associated with increased adverse outcomes in 519 critically ill patients (25). Despite the multicenter nature of the study, the cohorts still were also 520 predominantly Caucasian.

521 Future Directions

522 While the findings presented herein suggest assessing IFNγ production by ELISpot can be

523 useful in identifying sepsis patients at risk of long-term mortality and the immune suppressed 524 endotype, its discriminative ability is similar to SOFA and Charlson comorbidity indices and does not add significantly to their discriminative power. With that said, SOFA and Charlson 525 comorbidity indices are rarely used for clinical decision making because they provide no 526 insights or therapeutic directions into the immunological disturbances associated with sepsis 527 528 and adverse outcomes. Application of ELISpot to the clinical armamentarium has the potential 529 to provide important information regarding which sepsis patients would benefit from targeted therapy (precision medicine). For example, septic patients who have profound suppression of 530 531 stimulated IFNy production may be harmed by therapy with corticosteroids, but might be good candidates for immune adjuvants therapies to boost their ability to combat invading pathogens. 532 ELISpot is an FDA-cleared approach for assessing functional immune status to prior 533 534 tuberculosis infection and the ELISpot reader used in these studies (CTL S6 Entry) is FDA 535 510(k) cleared. However, to make these results more actionable, ELISpot results will need to be obtained within hours, instead of days. Currently, ELISpot results take at least 24 hours to 536 return, although preliminary data from our consortium suggests the assay can be modified to 537 produce results in less than 12 hours (Griffith, T and Caldwell, C., manuscript in preparation). 538

In addition, ELISpot can be readily used to assess other components of the blood innate and adaptive immune response simply by varying the stimulant and the readout metric. For example, innate immune responses have been readily assessed using endotoxin or other TLR ligands as a whole blood stimulant and TNF α as the readout (20,21). Furthermore, underlying mechanisms of adaptive or innate immune responses can be explored using alternative stimulants (30,31,55), simultaneous adjuvants or inhibitors (56), or different readout metrics (21,55).

24

546 Conclusions

547 ELISpot can assess functional immune status in critically ill patients, predict adverse long-term

⁵⁴⁸ outcomes, and identify subsets of patients who may benefit from immunostimulant therapy.

25

549 **Contributions:**

550 University of Florida

- 551 EAB –Investigation, Visualization, Writing-Review and Editing; PAE- Resources, Funding
- 552 Acquisition, Supervision, Writing-Review and Editing; ML-Investigation, Visualization; LEB-
- 553 Supervision, Investigation, Writing-Review and Editing; TL- Supervision, Investigation, Writing-
- 854 Review and Editing; VP- Investigation, Visualization, LLM- Conceptualization, Funding
- 555 Acquisition, Resources, Supervision, Project Administration, Writing-Review and Editing; **RU**-
- 556 Supervision, Investigation, Visualization, JPL- Supervision, Investigation, MD-Investigation,
- 557 Visualization, LZS-Investigation, Visualization, RD-Investigation, AM-Investigation

558 University of Iowa

- 559 EES- Investigation, Visualization; MH- Investigation, Visualization; PMcG -
- 560 Conceptualization, Project Administration; MR- Investigation, Visualization; VPB-
- 561 Conceptualization, Funding Acquisition, Resources, Supervision, Writing-Review and Editing

562 **University of Minnesota**

- 563 **RWG** Conceptualization, Project administration; **TSG** Conceptualization, Funding,
- 564 Acquisition, Resources, Supervision, Writing–Review and Editing; LH– Project Administration;
- 565 **TAK** investigation, visualization; **CN** project administration; **JX** investigation, visualization.

566 Washington University in St. Louis

- 567 **RSH-** Conceptualization, Funding, Acquisition, Resources, Supervision, Writing–Review and
- 568 Editing; DDT- Investigation, AD- Investigation, SM1-Investigation, SM2-Investigation, IT-
- 569 Conceptualization, Supervision, Writing-Review and Editing

570 University of Washington

571 **SB-** Conceptualization, Funding, Writing–Review and Editing

572 University of Cincinnati

- 573 CCC- Conceptualization, Funding, Acquisition, Resources, Supervision, Writing–Review and
- 574 Editing; **MDG** Acquisition, Investigation, Visualization, Supervision. **CBB** Acquisition,
- 575 Investigation

576 Case Western Reserve University

- 577 **MBM-** Conceptualization, Supervision, Investigation, Writing-Review and Editing; **KR-**
- 578 Conceptualization, Investigation, Acquisition, Writing-Review and Editing.
- 579
- 580

Acknowledgements: This work was directly supported by R01 GM-132364, awarded by the
 National Institute of General Medical Sciences, including a supplement (R01 GM-132364 03S1) in 2022-2024.

Additional support was provided by grants T32 GM-008721 (EAB, VP, PAE), RM1 GM-139690
(LLM, PAE), R01 GM-149657 (TL), R01 GM-124156 (MDG), R35 GM-140806 (PAE), R35 GM-133756 (IT), R35 GM-134880 (VB), R35 GM-134880 (SB), R35 GM1-40881 (TSG), R35 GM-12698 (RSH), all from the National Institute of General Medical Sciences, G102983-6263608307-1 (MDG) from Department of Defense, IK6BX006192 from the Department of Veteran Affairs (TSG), and BE 7016/1-1 (CD) from the Deutsche Forschungsgemeinschaft (German Research Foundation).

591 The authors also wish to gratefully acknowledge the patients and their families for their 592 willingness to participate in an observational clinical study with no direct benefit to them.

27

594 **References**

Bauer M, et al. Mortality in sepsis and septic shock in Europe, North America and
 Australia between 2009 and 2019- results from a systematic review and meta-analysis. *Crit Care*. 2020;24(1):239.

598 2. Cecconi M, et al. Sepsis and septic shock. *Lancet*. 2018;392(10141):75-87.

599 3. Hotchkiss RS, et al. Sepsis and septic shock. *Nat Rev Dis Primers*. 2016;2:16045.

4. Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic

601 Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.

5. Silva EE, et al. The Calm after the Storm: Implications of Sepsis Immunoparalysis on
Host Immunity. *J Immunol*. 2023;211(5):711-719.

604 6. Darden DB, et al. Biomarker Evidence of the Persistent Inflammation,

605 Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After

606 Surgical Sepsis. *Ann Surg.* 2021;274(4):664-673.

607 7. Efron PA, et al. The Persistent Inflammation, Immunosuppression, and Catabolism
608 Syndrome (PICS) Ten Years Later [published online August 8, 2023]. *J Trauma Acute Care*609 *Surg.* doi: 10.1097/TA.00000000004087.

610 8. de Nooijer AH, et al. Complement activation in severely ill patients with sepsis: no
611 relationship with inflammation and disease severity. *Crit Care*. 2023;27(1):63.

9. Roth WJ, et al. Characterization of two distinct transglutaminases of murine bone

28

613 marrow-derived macrophages: effects of exposure of viable cells to cigarette smoke on

enzyme activity. *J Leukoc Biol*. 1987;42(1):9-20.

van Oosterom A, Huiskamp GJ. The effect of torso inhomogeneities on body surface
 potentials quantified using "tailored" geometry. *J Electrocardiol*. 1989;22(1):53-72.

11. van der Poll T, et al. The immunopathology of sepsis and potential therapeutic targets. *Nat Rev Immunol.* 2017;17(7):407-420.

12. van der Poll T, et al. The immunology of sepsis. *Immunity*. 2021;54(11):2450-2464.

13. Cox MC, et al. The impact of sarcopenia and acute muscle mass loss on long-term

outcomes in critically ill patients with intra-abdominal sepsis. *J Cachexia Sarcopenia Muscle*.
 2021;12(5):1203-1213.

14. Zhang W, et al. CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation. *Front Immunol.* 2021;12:620386.

15. Rincon JC, et al. Immunopathology of chronic critical illness in sepsis survivors: Role of
abnormal myelopoiesis. *J Leukoc Biol.* 2022;112(6):1525-1534.

16. Maslove DM, et al. Redefining critical illness. *Nat Med.* 2022;28(6):1141-1148.

Fenner BP, et al. Immunological Endotyping of Chronic Critical Illness After Severe
Sepsis. *Front Med (Lausanne)*. 2020;7:616694.

18. Scicluna BP, et al. Classification of patients with sepsis according to blood genomic
endotype: a prospective cohort study. *Lancet Respir Med.* 2017;5(10):816-826.

Balch JA, et al. Defining critical illness using immunological endotypes in patients with
 and without sepsis: a cohort study. *Crit Care*. 2023;27(1):292.

20. Loftus TJ, et al. Overlapping but Disparate Inflammatory and Immunosuppressive

Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis.

636 Front Immunol. 2021;12:792448.

Mazer MB, et al. A Whole Blood Enzyme-Linked Immunospot Assay for Functional
Immune Endotyping of Septic Patients. *J Immunol.* 2021;206(1):23-36.

Bossuyt PM, et al. The STARD statement for reporting studies of diagnostic accuracy:
explanation and elaboration. *Ann Intern Med.* 2003;138(1):W1-12.

641 23. Gardner AK, et al. The Development of Chronic Critical Illness Determines Physical

⁶⁴² Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical

44 24. Jouffroy R, et al. Relationship between prehospital modified Charlson Comorbidity Index
and septic shock 30-day mortality. *Am J Emerg Med*. 2022;60:128-133.

Brakenridge SC, et al. Current Epidemiology of Surgical Sepsis: Discordance Between
Inpatient Mortality and 1-year Outcomes. *Ann Surg.* 2019;270(3):502-510.

648 26. Brakenridge SC, et al. Evaluation of a Multivalent Transcriptomic Metric for Diagnosing

649 Surgical Sepsis and Estimating Mortality Among Critically III Patients. JAMA Netw Open.

650 **2022;5(7):e2221520**.

651 27. Albareda MC, et al. Distinct Treatment Outcomes of Antiparasitic Therapy in

⁶⁴³ ICUs. Crit Care Med. 2019;47(4):566-573.

- Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines,
- 653 Chemokines, and T-Cell Phenotypes. *Front Immunol.* 2018;9:1958.
- 28. Shin KH, et al. CMV specific T cell immunity predicts early viremia after liver
- transplantation. *Transpl Immunol.* 2018;51:62-65.
- 29. Remy KE, et al. Severe immunosuppression and not a cytokine storm characterizes
- 657 COVID-19 infections. JCI Insight. 2020;5(17)
- 30. Puertas MC, et al. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1
- Reservoir in the Monitoring of Cure Strategies. *mBio*. 2021;12(3):e0056021.
- 660 31. Bonavia AS, et al. Comparison of Rapid Cytokine Immunoassays for Functional
- Immune Phenotyping. *Front Immunol*. 2022;13:940030.
- 662 32. Beckmann N, et al. Staging and Personalized Intervention for Infection and Sepsis.
- 663 Surg Infect (Larchmt). 2020;21(9):732-744.
- 33. Podd BS, et al. Early, Persistent Lymphopenia Is Associated With Prolonged Multiple
 Organ Failure and Mortality in Septic Children. *Crit Care Med.* 2023;
- 34. Denstaedt SJ, et al. Blood count derangements after sepsis and association with posthospital outcomes. *Front Immunol.* 2023;14:1133351.
- 35. Drewry AM, et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality.
 Shock. 2014;42(5):383-91.
- 36. Zidar DA, et al. Association of Lymphopenia With Risk of Mortality Among Adults in the

31

US General Population. *JAMA Netw Open*. 2019;2(12):e1916526.

37. Bidar F, et al. Concomitant Assessment of Monocyte HLA-DR Expression and Ex Vivo
TNF-alpha Release as Markers of Adverse Outcome after Various Injuries-Insights from the
REALISM Study. *J Clin Med.* 2021;11(1)

38. Bodinier M, et al. Monocyte Trajectories Endotypes Are Associated With Worsening in
Septic Patients. *Front Immunol.* 2021;12:795052.

39. Uzzan B, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after

surgery or trauma: a systematic review and meta-analysis. *Crit Care Med.* 2006;34(7):19962003.

40. Prkno A, et al. Procalcitonin-guided therapy in intensive care unit patients with severe
 sepsis and septic shock--a systematic review and meta-analysis. *Crit Care*. 2013;17(6):R291.

Wirz Y, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in
 intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of
 randomized trials. *Crit Care*. 2018;22(1):191.

42. Andriolo BN, et al. Effectiveness and safety of procalcitonin evaluation for reducing
mortality in adults with sepsis, severe sepsis or septic shock. *Cochrane Database Syst Rev.*2017;1(1):CD010959.

43. Tocu G, et al. The Contribution of Procalcitonin, C-Reactive Protein and Interleukin-6 in
the Diagnosis and Prognosis of Surgical Sepsis: An Observational and Statistical Study. *J Multidiscip Healthc.* 2023;16:2351-2359.

32

691 44. Patel RT, et al. Interleukin 6 is a prognostic indicator of outcome in severe intra-

abdominal sepsis. *Br J Surg.* 1994;81(9):1306-8.

45. Casey LC, et al. Plasma cytokine and endotoxin levels correlate with survival in patients
with the sepsis syndrome. *Ann Intern Med.* 1993;119(8):771-8.

46. Zeng C, et al. Predictive Value of Soluble Programmed Cell Death Ligand-1 in the

696 Progression of Septic Patients to Chronic Critical Illness in the Intensive Care Unit: A

Prospective Observational Clinical Study. *Shock*. 2023;60(2):163-171.

47. Derigs M, et al. Soluble PD-L1 in blood correlates positively with neutrophil and
negatively with lymphocyte mRNA markers and implies adverse sepsis outcome. *Immunol Res.* 2022;70(5):698-707.

48. Kostaki A, et al. A 29-Mrna Host Response Whole-Blood Signature Improves Prediction

of 28-Day Mortality and 7-Day Intensive Care Unit Care in Adults Presenting to the Emergency

Department with Suspected Acute Infection and/or Sepsis. *Shock.* 2022;58(3):224-230.

Galtung N, et al. Prospective validation of a transcriptomic severity classifier among
 patients with suspected acute infection and sepsis in the emergency department. *Eur J Emerg Med.* 2022;29(5):357-365.

50. Haem Rahimi M, et al. Fully automated interferon-gamma release assay to monitor
antigen-independent T cell functionality: A proof of concept study in septic shock. *Cytokine*.
2023;169:156263.

51. Kim TS, Shin EC. The activation of bystander CD8(+) T cells and their roles in viral

- 711 infection. *Exp Mol Med*. 2019;51(12):1-9.
- 52. Martin MD, et al. Bystander responses impact accurate detection of murine and human
- 713 antigen-specific CD8 T cells. *J Clin Invest.* 2019;129(9):3894-3908.
- 53. Freeman BE, et al. Regulation of innate CD8+ T-cell activation mediated by cytokines.
- 715 Proc Natl Acad Sci U S A. 2012;109(25):9971-6.
- 54. Cox MC, et al. Abdominal sepsis patients have a high incidence of chronic critical illness
- with dismal long-term outcomes. *Am J Surg.* 2020;220(6):1467-1474.
- 55. Malewicz NM, et al. Early suppression of peripheral mononuclear blood cells in sepsis
- in response to stimulation with cytomegalovirus, OKT3, and pokeweed mitogen. J Appl Physiol
- 720 *(1985)*. 2019;127(6):1539-1547.
- 56. Mazer M, et al. IL-10 Has Differential Effects on the Innate and Adaptive Immune
- 722 Systems of Septic Patients. *J Immunol*. 2019;203(8):2088-2099.

34

724 Table 1. Clinical Characteristics of Patient Cohorts and Healthy Control Subjects.

725 Patients included two cohorts of individuals admitted to the ICU, one presumed to be septic

(SEPSIS), a second presumed to not be septic, but critically ill and at risk of developing sepsis

727 (CINS). Values are obtained at time of admission to the ICU.

	CINS (n=68)	SEPSIS (n=107)	Healthy Control (n=46)	p value
Male [n (%)]	37 (54%)	62 (58%)	16 (35%)	0.0283
Age, years	59 (37, 67)	63 (51, 71)	47 (30, 62)	<0.0001
BMI, kg/m ²	27.3 (22.8, 33.9)	28.0 (22.7, 34.8)	N/C	0.718
SOFA Score	6 (4, 8)	6 (4, 10)	N/C	0.718
Charlson Comorbidity Score	2 (0, 4)	3 (1, 4)	2 (0, 2); n=19	0.0045
Total Leukocyte Cou	nts		·	
WBC (x10 ³ /µl)	9.3 (7.2, 12.6)	12.8 (8.9, 18.6)	6.5 (5.5, 7.5)	<0.0001
Monocytes (%)	6.9 (5.2, 9.2)	4.6 (3.0, 7.1)	6.9 (6.1, 8.0)	<0.0001
Monocytes (x10 ³ /µl)	0.7 (0.4, 0.9)	0.7 (0.4, 1.0)	0.4 (0.4, 0.6)	0.0210
Neutrophils (%)	78.1 (71.9, 86.3)	86.1 (81.5, 91.4)	10.9 (7.7, 15.9)	<0.0001
Neutrophils (x10 ³ /µl)	7.2 (5.1, 10.6)	59 (55.2, 64.3)	3.7 (2.8, 4.6)	<0.0001
Lymphocytes (%)	12.4 (7.2, 17.5)	6.0 (4.3, 9.0)	29.4 (25.6, 35.2)	<0.0001
Lymphocytes (x10 ³ /µl)	1.0 (0.7, 1.4)	0.8 (0.5, 1.2)	1.9 (1.5, 2.3)	<0.0001
Plasma Proteins				·
IL-10 (pg/ml)	18.3 (14.7, 20.7)	20.0 (14.8, 26.3)	17.4 (13.6, 20.8)	0.059
IL-6 (pg/ml)	35.5 (14.2, 155.9)	42.2 (19.9, 101.9)	5.83 (5.05, 6.92)	<0.0001
sPD-L1 (pg/ml)	157 (100, 229)	204.7 (125.0, 311.7)	78.5 (66.5, 93.7)	<0.0001
Procalcitonin (ng/ml)				

N/C, not collected

36

730 Table 2. Clinical Course and Clinical Outcomes in SEPSIS and CINS cohorts.

	CINS (n=68)	SEPSIS (n=107)	p value
LOS, days	10 (7, 14), n=66	13 (7, 21), n=106	0.016
ICU LOS, days	5 (3, 9), n=67	4 (2, 10)	0.904
Secondary infection	17 (29%)	52 (59%)	0.0003
Favorable discharge	52 (76%)	61 (57%)	0.0018
CCI	3 (4%)	15 (14%)	0.074
In-Hospital Mortality	1 (1.5%)	14 (13%)	
30-Day Mortality		12 (11%)	
180-Day Mortality		18 (17%)	
Disposition at discharge			
Home	25 (37%)	27 (25%)	0.104
LTAC	0	4 (3.7%)	0.017
IPR	17 (25%)	12 (11%)	0.104
Hospital	0	2 (1.9%)	0.406
Other	2 (2.9%)	2 (1.9%)	0.319
SNF	10 (15%)	21 (20%)	0.007
Residential facility	0	0	
Home with services	10 (15%)	21 (20%)	0.843
AMA	2 (2.9%)	1 (0.93%)	
Death	1 (1.5%)	14 (13%)	
Hospice facility	1 (1.5%)	2 (1.9%)	
Home with hospice	0	1 (0.93%)	

Sample sizes are identified in column headings except where missing values are noted for
 specific indices.

733

734 LOS, length of hospital stay

- 735 LICUS, length of ICU stays
- 736 CCI, chronic critical illness
- 737 LTAC, long term acute care facility
- 738 IPR, inpatient rehabilitation
- 739 SNF, specialized nursing facility
- 740 AMA, discharged against medical advice
- 741

38

742 Table 3. Selected Area Under the Receiver Operating Curve Discrimination for Primary

743 **Outcome Variables in the SEPSIS cohorts.** Values represent the mean and 95% confidence 744 intervals for the primary outcome variables: 180-Day Mortality, In-Hospital Mortality, Incidence 745 of Secondary Infection, Development of Chronic Critical Illness (CCI).

746

Criterion	Time Point	180-day mortality	In-Hospital Mortality	Secondary Infection	CCI
Age	Baseline	0.68 (0.54,0.81)	0.42 (0.28,0.57)	0.48 (0.35,0.60)	0.62 (0.46,0.77)
Charlson Comorbidity Score	Baseline	0.82 (0.70,0.95)	0.76 (0.61,0.91)	0.55 (043,0.67)	0.71 (0.59,0.83)
SOFA	Baseline	0.72 (0.57,0.88)	0.72 (0.55,0.88)	0.59 (0.46,0.71)	0.65 (0.49,0.81)
	Day 1	0.76 (0.62,0.90)	0.76 (0.60,0.92)	0.65 (0.53,0.77)	0.76 (0.66,0.87)
	Day 4	0.79 (0.65,0.93)	0.83 (0.67,0.98)	0.68 (0.56,0.80)	0.84 (0.74,0.93)
ELIspot Stimulated IENWTE	Day 1	0.73 (0.60,0.86)	0.69 (0.55,0.84)	0.56 (0.44,0.69)	0.60 (0.45,0.75)
	Day 4	0.79 (0.69,0.90)	0.74 (0.61,0.87)	0.51 (0.37,0.65)	0.62 (0.43,0.81)
ELIspot Stimulated IFNγ SFU	Day 4	0.74 (0.60,0.88)	0.65 (0.47,0.84)	0.52 (0.39,0.66)	0.64 (0.47,0.82)
ELIspot	Day 1	0.71 (0.57,0.85)	0.68 (0.51,0.85)	0.56 (0.44,0.69)	0.56 (0.41,0.71)
Stimulated IFNy SS	Day 4	0.66 (0.53,0.79)	0.70 (0.55,0.85)	0.60 (0.47,0.73)	0.52 (0.36,0.68)
% Lymphocytes	Day 1	0.68 (0.53,0.83)	0.62 (0.42,0.81)	0.58 (0.45,0.71)	0.53 (0.38,0.69)
Stimulated IFN _Y TE	Day 4	0.60 (0.45,0.76)	0.54 (0.32,0.75)	0.65 (0.52,0.78)	0.58 (0.34,0.71)
Absolute lymphocyte	Day 1	0.63 (0.45,0.81)	0.53 (0.31,0.75)	0.58 (0.50,0.72)	0.46 (0.27,0.65)
count	Day 4	0.67 (0.52,0.81)	0.64 (0.48,0.80)	0.64 (0.51,0.77)	0.65 (0.47,0.84)
sPD-L1	Day 4	0.67 (0.53,0.80)	0.68 (0.52,0.84)	0.59 (0.45,0.73)	0.57 (0.38,0.77)
IL-6	Day 4	0.63 (0.47,0.79)	0.56 (0.37,0. 75)	0.64 (0.50,0.77)	0.62 (0.43,0.8)
IL-10	Day 4	0.62 (0.45,0.79)	0.51 (0.31,0.72)	0.60 (0.46,0.73)	0.57 (0.43,0.71)
IL-8/CXCL8	Day 4	0.60 (0.45,0.75)	0.64 (0.49,0.79)	0.46 (0.33,0.60)	0.68 (0.54,0.83)

747 Scores in bold are values equal to or greater than 0.74

748 TE, total expression

749 SFU, number of spot forming units

750 SS, spot size

39

752 Table 4. Evidence of Immunosuppression in SEPSIS Patients with Reduced Stimulated

753 IFNγ Total Expression (TE) As Discriminated by ELISpot at Days 1 and 4 Post-ICU

Admission. The threshold for reduced TE was set at 80% sensitivity. On day 1 the specificity was 42.1% and on day 4 the specificity was 63.2%.

⁷⁵⁶

Day 1	ELISpot IFNγ TE <2334/μm ²) N=65	ELISpot IFNγ ΤΕ ≥2334 (/μm ^²) N=40	P-value
Age	64.2 (14.7)	54.6 (15.1)	0.002
Total WBC cell day 1 (x 10 ³ /ml)	13.9 (7.07)	15.7 (7.77)	0.158
Absolute Lymphocyte Count Day 1 (/μl ³)	980 (249)	1460 (600)	0.028
sPD-L1 day 1 (pg/ml)	315 (333)	263 (246)	0.311
IL-10, day 1 (pg/ml)	32.3 (70.0)	28.6 (37.7)	0.608
Outcome			Odds-ratio
180-day mortality	23.1%	7.5%	3.70 (1.00,13.7)
In-Hospital mortality	18.5%	5.0%	4.30 (0.91,20.3)
CCI	18.5%	7.5%	2.79 (0.74,10.6)
Second Infection	59.6% (6 missing)	58.8% (13 missing)	1.03 (0.43,2.49)

Day 4	ELISpot IFNγ TE <1755/μm ²) N=41	ELISpot IFNγ ΤΕ ≥1755 (/μm ²) N=51	P-value
Age	66.2(14.0)	58.1(15.7)	0.011

Total WBC cell day 1 (x 10 ³ /ml)	13.6(6.93)	15.4(8.18)	0.305
Absolute Lymphocyte Count Day 1 (/ml ³)	70.7 (197)	191 (580)	0.006
sPD-L1 day 1 (pg/ml)	337(248)	239(290)	0.007
IL-10, day 1 (pg/ml)	10, day 1 42.7(89.9) 24.0(27.7)		0.086
Outcome			Odds-ratio
Outcome 180-day mortality	29.3%	5.9%	Odds-ratio 6.62 (1.72,25.5)
Outcome 180-day mortality In-Hospital mortality	29.3% 19.5%	5.9% 5.9%	Odds-ratio 6.62 (1.72,25.5) 3.88 (0.96,15.7)
Outcome 180-day mortality In-Hospital mortality CCI	29.3% 19.5% 22.0%	5.9% 5.9% 7.8%	Odds-ratio 6.62 (1.72,25.5) 3.88 (0.96,15.7) 3.30 (0.94,11.7)

Table 5. Multivariate Logistic Regression to Discriminate Time to Mortality based on

762 Charlson Comorbidity and SOFA Scores and Day 4 ELISpot Stimulated IFNγ Total

Expression in SEPSIS Patients.

	Odds ratio	p value		
Model I: Standard clinical indices	only			
SOFA score Day 4	1.30 (1.12-1.50)	0.0003		
Charlson comorbidity score (CCS) baseline	1.48 (1.24-1.77)	<0.0001		
Model II: ELISpot indices only				
ELISpot IFNγ TE Day 4 (Negative of log) 1.44 (1.07-1.95) 0.017				
Model III: Standard clinical indices + ELISpot indices				
SOFA score Day 4 1.28 (1.		0.0008		
Charlson comorbidity score (CCS) baseline	1.48 (1.22-1.79)	<0.0001		
ELISpot IFNγ TE Day 4 (Negative of log)	1.29 (0.90-1.85)	0.165		

42

768 Supplementary Table 1. Demographics and Outcomes Between SEPSIS Patients who

769 **Survived or Died Within 180 Days after Sepsis.** Values represent the number of sample

770 measurements for each analyte.

	Survivors, n=89	Non-Survivors, n=18	p value
Male [n (%)]	53 (60%)	9 (50%)	0.454
Age, years	62 (48, 70)	66 (59, 80)	0.0166
BMI, kg/m ²	28.0 (22.8, 34.9)	25.5 (21.3, 34.6)	0.490
SOFA Score	6 (4, 8)	10 (5, 11)	0.0236
Charlson Comorbidity Score	2 (1, 4)	6 (4, 7)	<0.0001
Total Leukocyte Counts	Survivors, n=82	Non-Survivors, n=17	
WBC (x10³/μl)	12.9 (9.6, 19.0), n=85	11.0 (8.1, 17.0), n=18	0.371
Monocytes (%)	4.6 (3.1, 7.5), n=84	4.7 (2.6, 6.0)	0.645
Monocytes (x10³/μl)	0.7 (0.4, 1.0)	0.4 (0.3, 1.0)	0.264
Neutrophils (%)	86.1 (81.5, 91.4), n=81	85.0 (80.6, 90.9)	0.729
Neutrophils (x10 ³ /μl)	11.0 (8.0, 17.0)	8.8 (6.8, 13.4)	0.158
Lymphocytes (%)	6.5 (4.3, 9.4), n=84	5.9 (5.3, 8.5)	0.980
Lymphocytes (x10 ³ /µl)	0.8 (0.5, 1.2), n=84	0.7 (0.5, 1.3)	0.684
Plasma Proteins	Survivors,n=86	Non-Survivors, n=18	
IL-10 (pg/ml)	19.7 (14.8, 26.3)	21.2 (16.3, 29.1)	0.578
IL-6 (pg/ml)	48.9 (20.0, 187.9)	60.3 (25.9, 149.2)	0.730
sPD-L1 (pg/ml)	190 (117, 303)	275 (181, 403)	0.144
Procalcitonin (ng/ml)	993 (254, 3254)	1106 (298, 1810)	0.487
Clinical Outcomes	Survivors, n=89	Non-Survivors, n=18	p value

LOS, days	13 (8, 20), n=88	14 (7, 20)	0.812	
ICU LOS, days	4 (2, 9)	6 (2, 15)	0.551	
Secondary infection	42 (58%), n=73	10 (67%), n=15	0.512	
Favorable discharge	59 (66%)	2 (11%)	0.00002	
CCI	10 (11%)	5 (28%)	0.0652	
In-Hospital Mortality	1 (1%)	13 (72%)	<0.00001	
30-Day Mortality	0	12 (70%)	<0.00001	
180-Day Mortality	0	18 (100%)		
Disposition at discharge	26 (29%)	1 (6%)	0.035	
Home	4 (4%)	0		
LTAC	11 (12%)	1 (6%)	0 404	
IPR	2 (2%)			
Hospital	2 (2%)	0	0.319	
Other	19 (21%)	2 (11%)		
SNF	0	0		
Residential	21 (24%)	0		
facility	1 (1%)	0		
Home with services	1 (1%)	13 (72%)	<0.00001	
AMA	2 (2%)	0		
Death	0	1 (6%)		
Hospice facility				
Home with hospice				

44

773 Figure 1. Flow Diagram for Study Enrollment



45

Figure 2. Unstimulated and Stimulated IFNy Expression as Determined by ELISpot in 776 SEPSIS and CINS Patients, and Healthy Control Subjects on Days 1, 4, and 7 Following 777 ICU Admission. Values represent medians and individual subject responses. Panels A, B, C 778 are from unstimulated whole blood while Panels D, E, F are antiCd3/CD28 stimulated whole 779 780 blood. Note that the scales for unstimulated expression are logarithmic, whereas they are linear for stimulated expression to appropriately reflect the magnitude and heterogeneity of the 781 individual response. * p< 0.05, ** p<0.01, ***p<0.001, ****p<0.001 as determined by Kruskal-782 783 Wallace ANOVA and post-hoc analyses using the Dunn test. Values are two sided and represent raw p values. SFU, spot forming units. SS, spot size. TE, total IFNy expression. 784 Unstimulated ELISpot Total IFN γ Expression (TE) A. Day 1 B. Day 4 C. Day 7



Figure 3 – ELISpot Spot Forming Units (SFU) (Panels A, B, C) and Spot Size (SS) (Panels D, E, F) from Unstimulated Whole Blood in the Three Cohorts (Healthy Subjects, SEPSIS

and CINS). In unstimulated whole blood, SEPSIS and CINS cohorts demonstrated a

consistent increase in the number of cells (SFU) producing IFN γ , when compared to healthy subjects. * p<0.05, *** p<0.001, **** p<0.0001, as determined by Kruskal-Wallace ANOVA and

subjects. * p<0.05, *** p<0.001, **** p<0.0001, as determined by Kruskal-Wallace ANOVA and
 post-hoc analyses using the Dunn test. Values are two sided and represent raw p values.

793 SFU, spot forming units. SS, spot size. TE, total IFNγ expression.



47

797 Figure 4. Anti-CD3/CD28 Stimulated IFNγ Expression by ELISpot in Sepsis Patients

798 Measured at 1, 4 and 7 Days after ICU Admission who Survived or Did Not Survive by

180 days. Panels A, B, C reflect spot number, D, E, F, spot size, and G, H, I, total IFNγ
 expression. Values represent medians and individual subject responses. The number of

subjects declines over time as patients are either discharged from ICU or die. * p< 0.05, **

p<0.01, ***p<0.001, ****p<0.0001 as determined by Kruskal-Wallace ANOVA and post-hoc

analyses using the Dunn test. Values are two sided and represent raw p values. SFU, spot
 forming units. SS, spot size. TE, total IFNγ expression.



Figure 5. Area under the Receiver Operator Curves (AUROC) for Physiologic (SOFA, Charlson comorbidity scores) and Stimulated IFNγ ELISpot Responses in Differentiating In-Hospital and 180-day Mortality. Top Row: Panel A provides SOFA and Charlson

809 Comorbidity Index, and Panel B, selected ELISpot parameters discriminating 180 day

- 810 mortality. Lower Row: Same breakdowns as for the top row discriminating in-hospital
- 811 mortality. TE, IFNγ ELISpot total expression; SFU, IFNγ ELISpot spot forming units; SS







49

815 Supplemental Figure 1. Absolute Lymphocyte Counts in SEPSIS and CINS Cohorts at Different Time Intervals and Healthy Subjects. Whole blood was collected at different time 816 points and total and absolute lymphocyte counts were determined. Both SEPSIS and CINS 817 resulted in a significant decline in total lymphocytes when compared to healthy subjects on 818 days 1, 4 and 7, while absolute lymphocyte counts were lower in SEPSIS than in CINS 819 patients on day 1. Healthy control subjects were sampled only once but values are presented 820 at each time point for comparison. * p<0.05, *** p<0.001, **** p<0.0001 as determined by 821 Kruskal-Wallace ANOVA and post-hoc analyses using the Dunn test. Values are two sided 822 and represent raw p values. 823



824 825

50

827 Supplemental Figure 2. Percentage of Lymphocytes Expressing IFNγ in Whole Blood

from SEPSIS and CINS cohorts, and Healthy Subjects. The number of spot forming units
was compared to the absolute lymphocyte count and the percentage of lymphocytes producing

IFNγ was calculated. Regardless of time after enrollment, both SEPSIS and CINS markedly

increased the percentage of IFN γ -producing cells. * p<0.05, *** p<0.001, **** p<0.0001, as

determined by Kruskal-Wallace ANOVA and post-hoc analyses using the Dunn test. Values

are two sided and represent raw p values. SFU, spot forming units. SS, spot size. TE, total

834 IFNγ expression.

835



837 838	Supplemental Methods
839	Detailed specific criteria for consenting and enrolling SEPSIS and CINS patients, and healthy
840	control subjects are described below, as is sampling and processing procedures. Actual IRB
841	documentation and the Consortium Laboratory Manual are readily available by simply
842	requesting them from our data and sample broker, the UF Clinical and Translational Research
843	Institute Biorepository (https://www.ctsi.ufl.edu/research/laboratory-services/ctsi-biorepository-
844	2/scirc-specimens-archive/).
845	Recruitment methods
846	Screening for sepsis will be carried out using each hospital's own version of their sepsis alert
847	system, which quantifies derangements in vital signs, white blood cell count, and mental
848	status. After a putative diagnosis of sepsis, the patient is transferred to the ICU and sepsis
849	treatment bundles are initiated. If a patient is believed to have an infection and they are located
850	in, or transferred to the ICU, they are entered into each institution's sepsis management
851	protocol as standard of care which implements a variety of standard operating procedures
852	(SOPs) of clinical ICU care. After the patient enters the clinical management protocol, the
853	research coordinator is notified of a potential research subject. This coordinator will then
854	assess the following inclusion/exclusion criteria and consent the appropriate candidates.
855	All critically ill patients with or without sepsis will be managed via each institution's evidence-
856	based management protocols that emphasize early antibiotic administration, fluid resuscitation
857	and hemodynamic monitoring and support, consistent with current Surviving Sepsis Campaign
858	guidelines.
859	Consenting

52

860 Consent will be sought by clinical research staff, all of whom are familiar with institutional 861 logistics and infrastructure, sample acquisition and preparation, and are experienced in the nuances of enrollment and informed consent for this challenging patient population. Many 862 critically ill patients in the ICUs may have altered mental status or pharmacologic sedation, but 863 would be regarded as prospective research subjects. We will seek an IRB-approved 96-hour 864 delayed consent for blood sample acquisition and completion of the /T1 visit per protocol 865 866 (within the first 72 hours). This includes: study criteria evaluation, sample collection and transportation to clinical and research laboratories, collection of demographic information, and 867 868 collection of medical laboratory results to compliment research experiments. Additionally, we will seek approval for telephone consent in the event that no LAR is physically present. For the 869 ICU patient population, many of whom are pharmacologically sedated and mechanically 870 871 ventilated, initial consent is commonly requested from LAR/next of kin. The setting for 872 conveying consent information to LAR/next of kin is often the ICU family waiting area or at bedside. Consideration is given to the emotional status of the LAR/next of kin and ability to 873 understand the basic intent, methods, and voluntary nature of participation. If we need to call a 874 LAR, ideally we will email them a copy of the consent and review, record approval with a 875 876 witness on the line. If we can't email them, then we will review the entire consent over the 877 phone, record approval with a witness on the line.

The research staff will monitor the patient's progress and once they regain capacity, the patient will be re-consented. If patient does not regain capacity to consent by discharge, he/she will be consented at their next follow-up visit if capacity is regained.

53

- 881 For the healthy control subjects, we will send an email out to the Department of Surgery email
- distribution list to all department staff for recruiting healthy control participants. When the
- participant comes in for the blood draw we will review the consent and have them sign.
- 884 Specific Inclusion/Exclusion Criteria

885 SEPSIS- Presumed Sepsis Patients

886 Inclusion Criteria

887	Α.	Directly admitted ICU patients with sepsis (From ED or OR)
888		ICU patient developing sepsis during hospitalization.
889		Transferred to ICU from inpatient unit for development of sepsis.
890		Documentation in notes or diagnoses of "Sepsis", "Septic shock", "Severe Sepsis"
891	<u>or</u>	
892	В.	Suspicion of infectious cause of illness on admission
893		Documentation of suspected infection
894		Infectious testing performed (blood, urine, other cultures, viral or fungal testing)
895		Diagnostic testing: chest X-ray. CT scan of abdomen
896		Initiation of antimicrobial therapy (antibiotics, antivirals, antifungals)
897		Source control operation/procedure performed
898	<u>and</u>	
899		Organ dysfunction as defined as an acute change in total SOFA score of 2 points
900		consequent to the infection.
901		The baseline SOFA score can be assumed to be zero in patients not known to have
902		preexisting organ dysfunction.
903		
904	<u>Exclu</u>	sion Criteria
905		Patients deemed to be futile care or have advanced care directives or goals of care
906		limiting resuscitative efforts.
907		Severe traumatic brain injury (evidence of neurologic injury on CT scan and a GCS <8
908		after resuscitation).
909		Refractory shock (i.e., patients who are expected to die within 24hours).
910		Uncontrollable source of sepsis (e.g. irreversible disease state such as unresectable
911		dead bowel).
912		Outside facility transfer where suspected sepsis onset is >72 hours prior to ICU
913		admission.
914		Active chronic hepatitis or other chronic infectious diseases.
915		Known HIV infection with CD4 count <200 cells/mm ³ .
916		Organ transplant recipient on immunosuppressive agents.
917		Known pregnancy.
918		Prisoners.

54

- 919 Institutionalized patients.
- 920 Active cancer.
- 921 Any recent (past 6 months) chemotherapy or immunomodulatory therapies (including 922 biologics, monoclonal antibodies).
- 923 Patient having received steroids in past 4 weeks.
- 924

927

933

935

954

958

961

925 **CINS – Critically-ill non-sepsis patients**

- 926 Inclusion Criteria
- 928 A. Patients admitted to the SICU for non-infectious reasons
- 929 Trauma patients
- 930 Post-operative patients (not infectious source control procedures)
- Inpatients transferred to the SICU for non-infectious reasons (e.g., bleeding, volume
 overload, acute cardiac issue, ect.)
- 934 <u>Exclusion criteria</u>
- Patients deemed to be futile care or have advanced care directives or goals of care
 limiting resuscitative efforts.
- Severe traumatic brain injury (evidence of neurologic injury on CT scan and a GCS <8 after
 resuscitation).
- 940 Refractory shock (i.e., patients who are expected to die within 24hours).
- 941 Uncontrollable source of sepsis (e.g. irreversible disease state such as unresectable dead
 942 bowel).
- 943 Outside facility transfer where suspected sepsis onset is >72 hours prior to ICU admission.
- Active chronic Hepatitis or other chronic infectious diseases.
- 945 Known HIV infection with CD4 count <200 cells/mm3.
- 946 Organ transplant recipient on immunosuppressive agents.
- 947 Known pregnancy.
- 948 Prisoners.
- 949 Institutionalized patients.
- 950 Active cancer.
- Any recent (past 6 months) chemotherapy or immunomodulatory therapies (including
 biologics, monoclonal antibodies).
- 953 Patient having received steroids in past 4 weeks.
- 955 Healthy Control Subjects
- 956 957 Inclusion Criteria
- All adults (age >=18)
- Ability to obtain Informed Consent prior to blood collection.
- 962 Exclusion Criteria

55

- 963
- 964 Current, chronic steroid use
- 965 Pregnancy
- 966 Current or recent (within 7 days) use of antibiotics.
- 967

968 Sample Collection

969

970 The overview of research sample collection for SPIES clinical study are presented in 971 the Sample Collection Chart:

972

SPIES Sample Collection Chart									
	T1	T2	Т3	Т4	T5	Τ6			
	Day 1	Day 4	Day 7	Day 14	Day 21	Day 28 or discharge			
		(+/- 1)	(+/- 1)	(+/- 2)	(+/- 2)	(+/- 2)			
Whole Blood ELISpot (1ml), HLA-DR (1ml), Cytokines (4-8ml) - 6-10ml heparin (green)	х	х	х	х	х	Х			
(Optional) CBC w/diff - 2ml EDTA (purple)	Х	Х	Х	Х	Х	Х			
Gene Expression - 2.5ml PAXgene	X	X	Х	Х	Х	Х			
Total blood (ml)	8.5 - 14.5	8.5 - 14.5	8.5 - 14.5	8.5 - 14.5	8.5 - 14.5	8.5 - 14.5			

973

974

975 PLASMA PROCESSING

976 Administrative Note: All personnel involved in the procedures are to have completed the 977 University required Blood-Borne Pathogen training program, and provided suitable personal protection equipment (PPE). These procedures are to be performed whenever possible in a 978 biocontainment hood (BSL1 or BSL2). All solid or liquid waste derived from the blood must be 979 980 disposed of appropriately in a biohazard container or inactivated using bleach or an acceptable disinfectant. Venous or arterial whole blood is collected into the appropriate blood collection 981 tubes for each time point. The collection of blood should be obtained from an existing arterial 982 or venous line, or venipuncture should be performed by someone experienced in the 983

56

technique, and familiar with infectious precautions. The blood should be processed as soon as
possible, <u>but within 3 hours of the draw</u>. The blood should be <u>kept cold on ice</u> during the
period from the draw to the initiation of processing.

987 CBC with Differential

Each site must collect for and obtain a CBC with Differential at every patient sample time point. These must be collected at the same time as the study blood draws or as close to it as possible if done through the hospital's standard of care. This data must be entered into REDCap.

992 Plasma Collection

Invert the green heparin blood tube gently to thoroughly mix the blood. Transfer one ml
 of blood to a 15 ml conical (polyethylene or polystyrene) tube labeled HLA-DR. And transfer
 500 ul of blood to a 1.5 ml microcentrifuge tube labeled ELISpot.

996

2. After removing the blood needed for the ELISpot and Smart Tube assays in Step 1,
centrifuge the remaining blood in the green top heparin blood collection tube at room
temperature (22°C) for 10 minutes at 1,800 x g, with the brake on low.

1000

3. Once the tube has finished spinning, carefully transfer the plasma from the green top blood tube (take care not to disturb the cellular constituents) and aliquot 500 ul of plasma equally into 4-6 **green** capped plasma collection tubes. If there is any remaining plasma, collect and distribute evenly among all tubes.

57

- 1006 4. Make sure the appropriate *Heparin Plasma* barcode labels are attached to the tubes
- 1007 and immediately store at -80°C.